Xenetic Biosciences First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St

May 16, 2025

Xenetic Biosciences (NASDAQ:XBIO) First Quarter 2025 Results

Key Financial Results

Revenue: US$593.3k (up 16% from 1Q 2024).
Net loss: US$903.1k (loss narrowed by 24% from 1Q 2024).
US$0.59 loss per share (improved from US$0.78 loss in 1Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

earnings-and-revenue-history — NasdaqCM:XBIO Earnings and Revenue History May 16th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Xenetic Biosciences EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 13%. Earnings per share (EPS) exceeded analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 1.6% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 4 warning signs for Xenetic Biosciences (of which 2 are concerning!) you should know about.

If you're looking to trade Xenetic Biosciences, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.